Telcon RF Pharmaceutical텔콘RF제약
200230 · KOSDAQ · ₩200230 · 텔콘RF제약
₩2,150▲ ₩85 (4.12%)End-of-day · Oct 27, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩43B | ₩38B | ₩36B | ₩28B | ₩38B |
| Cost of sales | ₩33B | ₩28B | ₩27B | ₩22B | ₩29B |
| Gross profit | ₩10B | ₩10B | ₩9.6B | ₩5.7B | ₩9.1B |
| Operating income | ₩719M | −₩71M | ₩965M | −₩4.1B | −₩2.7B |
| Net income | −₩11B | −₩26B | ₩14B | −₩42B | −₩23B |
| Net income to shareholders | −₩11B | −₩26B | ₩14B | −₩42B | −₩23B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩157B | ₩154B | ₩140B | ₩119B | ₩168B |
| Current assets | ₩58B | ₩26B | ₩33B | ₩23B | ₩37B |
| Cash and equivalents | ₩26B | ₩3.3B | ₩8.5B | ₩9.7B | ₩23B |
| Total liabilities | ₩48B | ₩70B | ₩35B | ₩35B | ₩61B |
| Current liabilities | ₩46B | ₩70B | ₩35B | ₩34B | ₩60B |
| Borrowings | ₩32B | ₩55B | ₩26B | ₩29B | ₩54B |
| Total equity | ₩109B | ₩83B | ₩105B | ₩84B | ₩107B |
| Shareholders' equity | ₩109B | ₩83B | ₩104B | ₩84B | ₩107B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩1.7B | ₩1.2B | −₩1.1B | −₩2.1B | −₩359M |
| Capital spending | ₩320M | ₩5B | ₩1.9B | ₩819M | ₩2.3B |
| Free cash flow | ₩1.3B | −₩3.7B | −₩3B | −₩2.9B | −₩2.6B |
Consolidated where available. Amounts in won.
Also known as: Telcon RF Pharmaceutical / 텔콘RF제약 / 200230 / KRX:200230
Source: KRX statistical information